{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:18:52Z","timestamp":1770466732153,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"DOI":"10.7759\/cureus.103110","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:46:07Z","timestamp":1770399967000},"source":"Crossref","is-referenced-by-count":0,"title":["Tumor Necrosis Factor-Alpha (TNF-\u03b1) Inhibitor Treatment in Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Study of Comorbid Risks"],"prefix":"10.7759","author":[{"given":"Sreeya","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Beckham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kermanjot","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaryab","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kritin K","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig G","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg SR","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020, 82:1045-58. 10.1016\/j.jaad.2019.08.090","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.089","article-title":"Hidradenitis suppurativa: current and emerging treatments","volume":"82","author":"Goldburg SR","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol. 2020, 82:1061-82. 10.1016\/j.jaad.2019.08.089","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1492","article-title":"Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa","volume":"93","author":"Mozeika E","year":"2013","unstructured":"Mozeika E, Pilmane M, N\u00fcrnberg BM, Jemec GB. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol. 2013, 93:301-4. 10.2340\/00015555-1492","journal-title":"Acta Derm Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746396","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li J","year":"2021","unstructured":"Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis. Front Pharmacol. 2021, 12:746396. 10.3389\/fphar.2021.746396","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.960488","article-title":"Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation","volume":"13","author":"Chopra D","year":"2022","unstructured":"Chopra D, Arens RA, Amornpairoj W, et al.. Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation. Front Immunol. 2022, 13:960488. 10.3389\/fimmu.2022.960488","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley JW","year":"2018","unstructured":"Baddley JW, Cantini F, Goletti D, et al.. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin Microbiol Infect. 2018, 24:S10-20. 10.1016\/j.cmi.2017.12.025","journal-title":"Clin Microbiol Infect"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/jci39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller EA","year":"2009","unstructured":"Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009, 119:1079-82. 10.1172\/jci39143","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad C","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al.. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018, 9:25. 10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153084","article-title":"Alopecia secondary to anti-tumor necrosis factor-alpha therapy","volume":"90","author":"Ribeiro LB","year":"2015","unstructured":"Ribeiro LB, Rego JC, Estrada BD, Bastos PR, Pi\u00f1eiro Maceira JM, Sodr\u00e9 CT. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol. 2015, 90:232-5. 10.1590\/abd1806-4841.20153084","journal-title":"An Bras Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams EL","year":"2009","unstructured":"Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009, 48:716-20. 10.1093\/rheumatology\/kep080","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2450401","article-title":"The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa","volume":"2017","author":"Jim\u00e9nez-Gallo D","year":"2017","unstructured":"Jim\u00e9nez-Gallo D, de la Varga-Mart\u00ednez R, Ossorio-Garc\u00eda L, Albarr\u00e1n-Planelles C, Rodr\u00edguez C, Linares-Barrios M. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017, 2017:2450401. 10.1155\/2017\/2450401","journal-title":"Mediators Inflamm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen AR","year":"2018","unstructured":"Vossen AR, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018, 9:2965. 10.3389\/fimmu.2018.02965","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj A","year":"2022","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022, 23:3753. 10.3390\/ijms23073753","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03743-1","article-title":"Psychiatric comorbidities, inflammatory bowel disease, and urticaria in acne vulgaris patients undergoing isotretinoin treatment: a multicenter cohort study from the TriNetX database","volume":"317","author":"Verma KK","year":"2025","unstructured":"Verma KK, Koch RS, Friedmann DP, Tarbox MB, Tyring SK. Psychiatric comorbidities, inflammatory bowel disease, and urticaria in acne vulgaris patients undergoing isotretinoin treatment: a multicenter cohort study from the TriNetX database. Arch Dermatol Res. 2025, 317:183. 10.1007\/s00403-024-03743-1","journal-title":"Arch Dermatol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453965-tumor-necrosis-factor-alpha-tnf--inhibitor-treatment-in-hidradenitis-suppurativa-a-population-based-retrospective-cohort-study-of-comorbid-risks","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:46:08Z","timestamp":1770399968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453965-tumor-necrosis-factor-alpha-tnf--inhibitor-treatment-in-hidradenitis-suppurativa-a-population-based-retrospective-cohort-study-of-comorbid-risks"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.103110","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}